A recent study suggests that GLP-1 weight-loss medications such as semaglutide (the active agent in Ozempic and Wegovy) may produce smaller or shorter-lived benefits for people whose overeating is driven by emotions like depression, boredom, or anxiety, compared with those who overeat in response to external food cues.
Study overview and outcomes
Researchers in Japan followed 92 adults with type 2 diabetes who started GLP-1 therapy and assessed them at baseline, three months, and 12 months. They tracked body weight, body composition, dietary patterns and blood markers including glucose and cholesterol. Participants were grouped by predominant eating behavior: emotional eating (eating in response to negative feelings), external eating (reacting to sights, smells or availability of food), and restrained eating (conscious dietary restriction that can lead to cycles of restriction and overeating).
Across the full group, patients experienced reductions in weight, cholesterol and body fat percentage over the year of treatment. Improvements in blood glucose were observed but did not reach statistical significance. When outcomes were analyzed by eating behavior, people with external eating patterns showed larger and more durable improvements. Those classified as emotional or restrained eaters tended to return toward their baseline habits by the one-year mark, limiting the long-term effectiveness of the medication for those subgroups.
Why emotional eating may blunt drug effects
GLP-1 receptor agonists reduce appetite and blunt physiological hunger signals, which helps curb calorie intake driven by true hunger or by environmental food cues. However, when overeating functions as an emotional coping strategy, lowering physiological appetite alone does not address the psychological triggers. As the study’s senior author noted, these drugs are less likely to fully address weight gain that stems primarily from emotional eating.
Clinical implications and expert perspectives
Several clinicians emphasize the value of assessing a patient’s relationship with food before starting pharmacologic or surgical weight-loss interventions. Bariatric surgeon Mir Ali advised that patients suspected of emotional eating should receive mental health evaluation before pursuing surgery or medications. Nutrition and obesity experts recommend tailoring treatment to the individual’s drivers of overeating: addressing mood, stress and coping skills in emotional eaters and focusing on environmental management for external eaters.
Dietitian Kristin Kirkpatrick highlighted that, despite the study’s small sample, the findings reinforce the need to combine medication with education and behavioral support. That combination can promote mindful or intuitive eating and help patients prepare for the possibility of reverting to old patterns if the drug is stopped.
Practical approaches by eating pattern
– External eating: Appetite-suppressing medications may be especially useful because they reduce reactivity to food cues. Behavioral strategies can also target trigger management and environmental changes to limit impulsive eating.
– Emotional eating: Psychological therapies and stress-management interventions are important to develop healthier coping strategies. Addressing mood disorders and teaching alternatives to comfort eating helps break cycles of craving and overeating.
– Restrained eating: Encouraging a balanced, non-restrictive relationship with food and using intuitive-eating principles can reduce bingeing and guilt-driven cycles.
Broader context
Obesity affects a large share of the population—about 40% of U.S. adults. Semaglutide-based drugs (Ozempic, Wegovy) and newer agents such as tirzepatide (Mounjaro, Zepbound) are prominent tools for weight loss and diabetes care. These medications act on physiological appetite pathways and can be highly effective for many people, but they do not automatically resolve psychological or behavioral drivers of overeating. Combining pharmacotherapy with long-term psychological support, nutrition counseling and lifestyle strategies is more likely to produce durable weight-loss maintenance and reduce the risk of regain when treatment stops.